Biotech Innovations: Understanding 23andMe's Transition from Success to Bankruptcy
Monday, 19 May 2025, 07:43
Biotech Innovations: A Timeline of 23andMe
This article presents a detailed timeline covering significant events in the life of 23andMe, illustrating the flow from success to bankruptcy in the biotech sector.
Key Events
- 2006: Co-founders Anne Wojcicki, Linda Avey, and Paul Cusenza establish 23andMe.
- 2007: Launch of the first direct-to-consumer genetic testing kit.
- 2008: Recognition as a leading figure in the DNA-testing industry.
- 2023: Company files for bankruptcy amid declining sales and a data breach crisis.
Drugmaker Regeneron Pharmaceuticals is acquiring majority assets of bankrupt genetic testing firm 23andMe Holding for $256 million.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.